Multi-action, a large number of commonly used drug health insurance will no longer be reimbursed

"Pharmaceutical Network Industry Dynamics" Recently, Shaanxi Province forwarded the provincial health insurance bureau, the provincial Human Resources and Social Security Department notice, requiring January 1, 2021, aluminum hydroxide gel and other 63 kinds of drugs will be unified out of the province's health insurance payment range.
In fact, since this year, from the provinces issued additional drug transfer notice frequency can be seen that the local medical insurance transfer is accelerating, in addition to Shaanxi Province, according to incomplete statistics, from January 1 next year, Qinghai, Anhui, Henan and so on have a number of drugs to stop medical insurance reimbursement.
such as October 10, Qinghai Health Insurance Bureau issued "on the issuance of Qinghai Province to supplement the drug digestion directory notice", decided to Qinghai Province to add 227 drugs out of health insurance.
According to the transfer arrangement, in 2020, a total of 129 varieties of drugs not used by the state-focused drug control and the drug procurement platform in Qinghai Province in the previous year will be transferred, and medical insurance and work injury insurance will be discontinued from January 1, 2021.
2022, the remaining 98 varieties will be transferred, and from January 1, 2023 to stop medical insurance, work injury insurance payments.
On June 8, the Chongqing Municipal Health Insurance Bureau issued the "Public Notice on the List of Health Insurance Class B Drugs for Progressive Digestion of Local Supplements in Chongqing" (hereinafter referred to as "PublicIty"), which also established the three-year digestion principle for Medical Insurance Class B drugs added by Chongqing Municipality, which contains a variety of common medications such as amoxilin, vitamin B12 and a number of large varieties of procurement.
In addition, the digestion schedule is determined to be: 193 digestive drugs in the first year, a proportion of 48%, from January 1, 2021 to stop medical insurance reimbursement;
addition, according to industry news, Henan Provincial Health Insurance Bureau announced the transfer of medical insurance list of drugs have also been notified to all departments, including 180 Western medicine and 140 Chinese medicine.
, according to the Henan Provincial Health Insurance Bureau notice, Henan Province's medical insurance drug catalog is not in the national health insurance directory of drugs will be transferred out of all at once (except ethnic drugs).
will implement the National List of Essential Medical Insurance, Industrial Injury Insurance and Health Insurance Drugs (2019 edition) from 1 January 2021.
According to incomplete statistics, Shaanxi Province this published directory, coupled with the previous, Qinghai, Anhui, Henan and other provinces issued a notice of the transfer of additional drugs, at least 864 varieties must be transferred by January 1, 2021 catalog, health insurance is no longer paid.
involved in brain communication, timishatan tablets, puddi blue anti-inflammatory oral solution and other best-selling drugs, commonly used drugs.
In fact, according to the June 17th, the State Health Insurance Administration, the Ministry of Finance and the State Administration of Taxation issued a Notice on Doing a Good Job in Basic Medical Security for Urban and Rural Residents in 2020, which calls for the gradual harmonization of the scope of payment of medical insurance drugs, the establishment of a monitoring mechanism for the implementation of negotiated medicines, and the formulation of additional provincial supplements. Variety three-year digestion program, by the end of June 2020 will be the national key monitoring varieties out of the catalog and complete 40% of the provincial added varieties of digestion, before the end of the year, the provinces will further speed up the clean-up work, a large number of varieties will be withdrawn from health insurance.
, with the promotion of local policies, a large number of varieties will withdraw from health insurance in the future has become a trend, the future pattern of the pharmaceutical market will change.
this may also face the problem of transformation or transfer to some medical representatives.
for pharmaceutical companies should actively adjust marketing strategies, such as accelerating consistency evaluation or focusing on research and development innovation, in the potential varieties of sufficient articles, etc., in order to win in the future market.